

IN THE SPECIFICATION

Please amend the specification as shown below and in Appendix 2, attached hereto. In particular, please replace the paragraph on page 11, lines 30-35 to page 12, lines ° to 5 with the following paragraph:

92
At least one or more mutant *ras* peptides may be administered in a dose of about 0.05 mg to about 10 mg per vaccination of the mammal, preferably about 0.1 mg to about 5 mg per vaccination. Several doses may be provided over a period of weeks as indicated. In one embodiment a dose is provided every month for 3 months. The mutant *ras* peptide may be administered alone or in combination with adjuvants, in a liposome formulation, cytokines, biological response modifiers, or other reagents in the art that are known to enhance immune response. Adjuvants include but are not limited to RIBI Detox™ (comprising mycobacterial cell wall skeleton and monophosphoryl lipid A), QS21, alum and incomplete Freund's adjuvant. In one embodiment, the mutant *ras* peptide is administered in combination with Detox™ (RIBI Immunochem, Hamilton, MT).

REMARKS

Claims 10-15, 25, 27, 32-34, 66-68, and 70 are pending in the application.

Claim 34 has been amended to omit a trademark/trade name, and include a description of the trademarked formulation. In addition, the specification has been amended to include a description of the trademarked formulation. No new matter has been added as a result of these amendments. The subject matter of the amendments is fully supported by, *inter alia*, Example 1 in the application as originally filed.